JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(4):238-242 | DOI: 10.36290/csf.2025.039

Radiopharmaceutical 68Ga-PSMA-11 for prostate cancer diagnostics

Michal Budinský, Ján Melicherík, Petr Vyšinský
Masarykův onkologický ústav, Ústavní lékárna, Úsek přípravy radiofarmak, Brno

Introduction: Radiopharmaceutical 68Ga-PSMA-11 represents gallium-68 radiolabeled peptide, molecular target for prostate-specific membrane antigen (PSMA) in prostate cancer.

Objective: The aim of this paper is to describe the experience with this radiopharmaceutical in view of radiopharmaceutical technology of preparation and radiopharmaceutical analysis.

Methods: This work studies and evaluates quality parameters of radiopharmaceutical 68Ga-PSMA-11.

Results: Quality parameters of radiopharmaceutical 68Ga-PSMA-11 prepared at our department from kits for radiopharmaceutical and radionuclide generator 68Ge/68Ga are in conformity with specification almost in 99 %.

Conclusion: Thanks to commercial availability of this peptide in the form of kit for radiopharmaceutical and radionuclide from radionuclide generator 68Ge/68Ga, it is possible to prepare it at the department of nuclear medicine without good manu­facturing practice conformity requirements.

Keywords: 68Ga-PSMA-11, prostate cancer, radiopharmacy, radiopharmaceutical, gallium-68.

Accepted: November 21, 2025; Published: December 5, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Budinský M, Melicherík J, Vyšinský P. Radiopharmaceutical 68Ga-PSMA-11 for prostate cancer diagnostics. Čes. slov. farm. 2025;74(4):238-242. doi: 10.36290/csf.2025.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 5.12.2026

    References

    1. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486-495. DOI: 10.1007/s00259-012-2298-2. Go to original source... Go to PubMed...
    2. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer. J Nucl Med. 2013;54(3):380-387. DOI: 10.2967/jnumed.112.111203. Go to original source... Go to PubMed...
    3. Hillier SM, Maresca KP, Lu G, et al. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer. J Nucl Med. 2013:54(3). 1369-1376. DOI: 10.2967/jnumed.112.116624. Go to original source... Go to PubMed...
    4. Eder M, Neels O, Müller M, et al. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 2014;7(7):779-796. https://doi.org/10.3390/ph7070779. Go to original source... Go to PubMed...
    5. Ferda J, Vokurka S, Ferdová E, et al. Podání ligandu prostatického specifického membránového antigenu 68Ga-PSMA-11 pro zobrazením nádorů prostaty pomocí PET/CT a PET/MR - iniciální zkušenosti s tolerancí podané látky a kvalitou zobrazení. Čes radiol. 2018;72(1):51-57. Go to original source...
    6. Ferda J, Ferdová E, Pernický J, et al. Zobrazení karcinomu prostaty pomocí PET/CT a PET/MR s podáním 68Ga-PSMA-11. Čes radiol. 2021;75(1):31-44. Go to original source...
    7. Budinský M, Vyšinský P, Řehák Z, et al. Zkušenosti s přípravou 68Ga-PSMA-11. Chem Listy. 2022;116(2):746-750. Go to original source...
    8. Rodríguez-Fraile M, Alonso PT, Rosales JJ, et al. The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma. Rev Espan Med Nucl Imag Mol. 2022;41(2):126-135. DOI: 10.1016/j.remnie.2022.02.001. Go to original source... Go to PubMed...
    9. Müller J, Ferraro DA, Muehlematter UJ, et al. Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imag. 2019;46(4):889-900. https://doi.org/10.1007/s00259-018-4203-0. Go to original source... Go to PubMed...
    10. Pastorino S, Riondato M, Uccelli L, et al. Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications. Curr Rad. 2020;13(1):63-79. DOI: 10.2174/1874471012666190729151540. Go to original source... Go to PubMed...
    11. Olivier P, Giraudet A, Skanjeti A, et al. Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study. J Nucl Med. 2023;579-585. DOI: 10.2967/jnumed.122.264743. Go to original source... Go to PubMed...
    12. Alberts A, Bütikofer L, Rominger A, et al. A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale. PLoS ONE 17(7): e0270269. 2022. https://doi.org/10.1371/journal.pone.0270269. Go to original source... Go to PubMed...
    13. Mojsak M, Szumowski P, Amelian A, et al. Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL. Cancers. 2023;15(16): https://doi.org/10.3390/cancers15164185. Go to original source... Go to PubMed...
    14. Wang IE, Morrissette LJ, Wong KK, et al. A comparison of routine [68Ga)Ga PSMA 11 preparation using Locametz and Illuccix kits. EJNMMI Radiopharmacy and Chemistry. 2024;9(84). https://doi.org/10.1186/s41181-024-00317-4. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.